PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
611 episodes - English - Latest episode: 11 days ago - ★★★★★ - 7 ratingsPeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice
May 19, 2022 23:00 - 1 hour VideoGo online to PeerView.com/PYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting...
Henry M. Kuerer, MD, PhD, FACS - Expanding the Benefits of PARP Inhibitor Therapy to More Patients With Breast Cancer and Earlier Disease Settings: Multidisciplinary Perspectives on How to Maximize the Potential of PARP Inhibitors and Optimize Their Use as Part of Multimodal Management of Breast Cancer
May 19, 2022 23:00 - 1 hour VideoGo online to PeerView.com/VHX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting...
Nina Shah, MD - Mapping the Therapeutic Odyssey in Multiple Myeloma: Interprofessional Guidance on Evidence-Based Treatment Selection and Sequencing
May 19, 2022 23:00 - 1 hour VideoGo online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including ...
Bhavana Pothuri, MD, MS - Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer
May 16, 2022 23:00 - 28 minutes VideoGo online to PeerView.com/KWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the role of immune checkpoint inhibitors in the care of patients with recurrent and advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Implement appropriate strategies for biomarker testing and integration of novel immunotherapy options into personalized managem...
Elizabeth Eaman, MD - Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations
May 16, 2022 23:00 - 1 hour VideoGo online to PeerView.com/YDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It is estimated that there are about 1 million adults in the United States who identify as transgender, and this number may be higher depending on the surveys used, the questions asked, and the diversity of subcultures within the transgender community. Although being transgender is not in itself a medical condition, transgender individuals have unique healthcar...
John J. Russell, MD - Cancer Control Through Early Blood-Based Detection: Perspectives on Integrating Innovative Multicancer Early Detection Tests in the Primary Care Setting
May 05, 2022 23:00 - 29 minutes VideoGo online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel’s take on the potential of blood-based cancer screening, the implications of emerg...
Bradley J. Monk, MD, FACS, FACOG - When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum
May 04, 2022 23:00 - 57 minutes VideoGo online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will...
Tanios Bekaii-Saab, MD - Dialing in the Dose: Reviewing Recent Evidence and Team-Based Strategies to Personalize and Optimize Patient Care in Metastatic Colorectal Cancer
May 04, 2022 23:00 - 34 minutes VideoGo online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and ...
Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies
April 29, 2022 23:00 - 58 minutes VideoGo online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates (ADCs) are showing great promise in improving outcomes in patients who currently have limited options. How should patients who would benefit from these novel ADCs be identifie...
Anthony R. Mato, MD, MSCE - Solving the Challenge of Tumor Lysis Syndrome: Expert Insight and Guidance on a Challenging Oncologic Emergency
April 29, 2022 23:00 - 32 minutes VideoGo online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they exp...
Sumanta Kumar Pal, MD, FASCO - Navigating Evolving Standards of Care in Renal Cell Carcinoma: Expert Insights on Selecting and Sequencing Targeted and Immunotherapy Options and a Look at Emerging Strategies
April 22, 2022 23:00 - 1 hour VideoGo online to PeerView.com/TRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to bring the new standard of care for advanced renal cell carcinoma (RCC) into your clinical practice? Join PeerView and KCCure to learn what the latest research on multi-targeted TKIs, immune checkpoint inhibitors, and combination strategies (dual checkpoint blockade and immune checkpoint inhibitor/TKI combinations) means for your patients with a...
Geoffrey Barnes, MD, MSc - Primary Care Call to Action for VTE Management: Sharpening Skills in Recognition, Treatment, and Secondary Prevention
April 22, 2022 23:00 - 1 hour VideoGo online to PeerView.com/TFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in the management of venous thromboembolism (VTE) discuss the importance of a timely diagnosis, appropriate treatment selection, and extended anticoagulation therapy for secondary prevention. Upon completion of this activity, participants should be better able to: Apply appropriate evidence-based clinical decision tools in an inter...
Henry M. Kuerer, MD, PhD, FACS / Heather L. McArthur, MD, MPH - Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches
April 13, 2022 23:00 - 57 minutes VideoGo online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 Intern...
Milind Javle, MD - Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine
April 11, 2022 23:00 - 1 hour VideoGo online to PeerView.com/DRJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to bring modern approaches to the treatment of patients with biliary cancers to your clinical practice? Learn how the treatment paradigm is shifting from conventional chemotherapy to biomarker-guided treatments and immunotherapy in a new event from PeerView and the Cholangiocarcinoma Foundation. Our experts will offer learners a deep dive into ...
Cindy Neunert, MD, MSCS - Modern Management of ITP: Thinking Beyond the Conventional Therapies
April 08, 2022 23:00 - 33 minutes VideoGo online to PeerView.com/GAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated, visually-enhanced activity, an expert in hematology-oncology discusses current standards for diagnosing and treating idiopathic thrombocytopenic purpura—and provides an update on the challenges associated with modern care and the promise of novel therapeutic options for disease management. Upon completion of this CE activity, participants will...
Petros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions
April 06, 2022 23:00 - 1 hour VideoGo online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug ...
Nasser Altorki, MD / Jonathan D. Spicer, MD, PhD, FRCSC - Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?
April 04, 2022 23:00 - 1 hour VideoGo online to PeerView.com/CRA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to the early-stage setting and transforming the multimodal management of resectable stage I-III NSCLC. While remarkable data have emerged from several trials assessing ICIs and rational combinations in neoadjuvant and/or adjuvant settings, many questions remain. What are the pros/...
Jennifer Wargo, MD, MMSc - Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options
April 01, 2022 23:00 - 54 minutes VideoGo online to PeerView.com/WUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the practice-changing evidence supporting the use of immunotherapy in resectable melanoma? In this activity, a panel of surgical and medical oncology experts will guide you through these new developments and provide insights on the real-world use of immunotherapy in resectable melanoma, including expanded applications of immunotherapy. The...
Stephen V. Liu, MD - Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors
March 31, 2022 23:00 - 28 minutes VideoGo online to PeerView.com/BNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the expanding role of macrocyclic TKIs in the treatment of fusion-positive NSCLC and other solid tumors. Upon completion of this activity, participants should be better able to: Discuss the structure and mechanisms of action of macrocyclic tyrosine kinase inhibitors (TKIs) and their role in the treatment of fusi...
Robert Dreicer, MD, MS, MACP, FASCO - Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults
March 30, 2022 23:00 - 1 hour VideoGo online to PeerView.com/GZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Clinicians who treat patients with prostate cancer have new opportunities to improve outcomes across a variety of settings, but the rapid expansion of treatment options has also presented dilemmas for those trying to choose the right treatment for the right patient. For instance, next-generation anti-androgen agents have proven efficacious in early stages of pr...
Mark S. Freedman, MD - Leveraging S1PR Modulators to Provide Patient-Centered MS Care: An Expert-Driven Review of the Data
March 29, 2022 23:00 - 33 minutes VideoGo online to PeerView.com/KAP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this expert-led activity, you will learn to leverage S1PR modulators to provide patient-centered MS care Upon completion of this activity, participants should be better able to: Identify the mechanisms of action for S1PR modulators approved for the treatment of multiple sclerosis in the context of disease pathophysiology. Assess the benefits and risks associ...
Richard S. Finn, MD - Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape
March 29, 2022 23:00 - 1 hour VideoGo online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar an...
"Mark S. Freedman, MD - Leveraging S1PR Modulators to Provide Patient-Centered MS Care: An Expert-Driven Review of the Data"
March 29, 2022 23:00 - 33 minutes VideoGo online to PeerView.com/KAP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this expert-led activity, you will learn to leverage S1PR modulators to provide patient-centered MS care Upon completion of this activity, participants should be better able to: Identify the mechanisms of action for S1PR modulators approved for the treatment of multiple sclerosis in the context of disease pathophysiology. Assess the benefits and risks associ...
Boris Sepesi, MD / Tina Cascone, MD, PhD - Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do
March 16, 2022 23:00 - 59 minutes VideoGo online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Convers...
Anthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers
March 16, 2022 23:00 - 1 hour VideoGo online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these ques...
Michael Heinrich, MD - Optimally Sequencing Modern TKIs in GIST: Expert Perspectives From an Interprofessional Sarcoma Team
February 23, 2022 23:00 - 1 hour VideoGo online to PeerView.com/CPH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While TKIs have been a mainstay in the first three lines of treatment for patients with gastrointestinal stromal tumors (GISTs), new discoveries and emerging science have led to the development of newer agents that address treatment resistance. Known as modern TKIs, these agents have a confirmed role in the treatment of patients with specific mutations or in la...
William D. Tap, MD - Practice Points in TGCT: Updates on Safe Use of Novel Systemic Options
February 23, 2022 23:00 - 18 minutes VideoGo online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safe...
Professor Thomas Powles, MBBS, MRCP, MD - Carrying Through in Advanced/Metastatic Urothelial Carcinoma: Expert Perspectives on Recent Practice‐Changing Data and the Practicalities of Individualizing and Continuing Care With Novel Immunotherapy Maintenance Strategies
February 22, 2022 23:00 - 55 minutes VideoGo online to PeerView.com/RVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Improving outcomes for patients with advanced urothelial carcinoma (UC) has been challenging, with many patients experiencing only short periods of progression-free survival after treatment with first-line chemotherapy. A game changer in many cancers, immunotherapy has provided new avenues for the cancer care team to help their patients with advanced UC live lo...
Suzanne Lentzsch, MD, PhD - A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey
February 22, 2022 23:00 - 1 hour VideoGo online to PeerView.com/HYJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibodies have allowed clinicians to bring their “A” game when managing multiple myeloma (MM). To see how this happened, watch this activity, developed in collaboration with HealthTree Foundation, to view how experts have rapidly integrated CD38, SLAMF7, and BCMA antibodies into the management of newly diagnosed and relapsed/refractory disease. Each case-based...
Carlos M. de Castro, MD - Upstream and Downstream Targeting of the Complement Pathway to Manage PNH: Current and Emerging Inhibitors
February 17, 2022 23:00 - 21 minutes VideoGo online to PeerView.com/YQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hematology-oncology provides an overview of paroxysmal nocturnal hemoglobinuria (PNH) and discusses current and emerging treatment options for managing PNH. Upon completion of this CE activity, participants will be able to: Discuss the complement pathway and its mechanistic relationship to paroxysmal nocturnal hemoglobinuria (PNH)...
Grzegorz (Greg) Nowakowski, MD - Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care
February 15, 2022 23:00 - 1 hour VideoGo online to PeerView.com/GWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The transformation of patient care in diffuse large b-cell lymphoma (DLBCL), driven by advances with antibodies and cellular therapy, continues—what will this mean for your practice? Find out in PeerView’s “Clinical Consults” video activity where a panel of DLBCL will focus on the applications of these dual innovations in the management of DLBCL. Using a series...
Sara M. Tolaney, MD, MPH - New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor Therapy
February 03, 2022 23:00 - 29 minutes VideoGo online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new...
Biree Andemariam, MD - The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities
February 01, 2022 23:00 - 1 hour VideoGo online to PeerView.com/CMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in sickle cell disease discuss current and future disease management strategies, including recent safety, efficacy, and tolerability data for currently approved and emerging therapies. Upon completion of this CE activity, participants will be able to: Discuss the disease burden, etiopathogenesis, complications, and unmet needs associat...
Erika Hamilton, MD - Expanding Treatment Options in ER+/HER2- Breast Cancer: Expert Perspectives on the Rapidly Emerging Role of SERDs, SERMs, and SERCAs, and the Practical Considerations of Leveraging Established and Innovative Therapies
January 28, 2022 23:00 - 1 hour VideoGo online to PeerView.com/HCA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in breast cancer discuss the latest advances in the management of patients with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2-) breast cancer, including the rapidly accumulating evidence supporting the use of novel therapies such as selective estrogen receptor degraders (SERDs), selective estr...
Nathan H. Fowler, MD - A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care
January 26, 2022 23:00 - 1 hour VideoGo online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also provi...
Steven Brem, MD - A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic Approaches
January 26, 2022 23:00 - 56 minutes VideoGo online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with t...
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Stage Disease
January 24, 2022 23:00 - 1 hour VideoGo online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions rem...
John C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management
January 20, 2022 23:00 - 1 hour VideoGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of...
Christopher Baugh, MD, MBA & Mark M. Awad, MD, PhD - Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice
January 20, 2022 23:00 - 1 hour VideoGo online to PeerView.com/KKF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with cancer often present to the ED in an acutely ill state with complications from their cancer or treatments used, but a broadening use of a new class of cancer immunotherapies has changed the types of complications experienced by these patients. This spectrum of unique toxicities, termed immune-related adverse events (irAEs), is less well known, and...
John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci - Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management
January 12, 2022 23:00 - 1 hour VideoGo online to PeerView.com/FZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Test yourself and take a tour with a “Tumor Board” on modern care for chronic lymphocytic leukemia (CLL). This activity, developed in collaboration with the CLL Society, features a panel of leading CLL experts blending serial, case-based discussion with mini seminars designed to illustrate how the personalized use of targeted therapeutics—including BTK and BCL-...
Robert Dreicer, MD, MS, MACP, FASCO/Pedro C. Barata, MD, MSc - Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer
January 11, 2022 23:00 - 56 minutes VideoGo online to PeerView.com/TGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the multidisciplinary relationship between urologic oncologists and advanced practice clinicians in the management of patients with prostate cancer has become increasingly more important in providing the best patient care. During this video, an expert panel highlights how a multidisciplinary team can use the latest clinical evidence, treatment ...
Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers
January 11, 2022 23:00 - 1 hour VideoGo online to PeerView.com/DVD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, multidisciplinary oncology experts discuss immunotherapy advances, focusing on transitioning immunotherapies to earlier disease settings to improve outcomes, prevent recurrences, and increase curability in early-stage cancers. Upon completion of this CE activity, participants will be able to: Describe the rationale for using neoadjuvant, adjuv...
"Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers"
January 11, 2022 23:00 - 1 hour VideoGo online to PeerView.com/DVD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, multidisciplinary oncology experts discuss immunotherapy advances, focusing on transitioning immunotherapies to earlier disease settings to improve outcomes, prevent recurrences, and increase curability in early-stage cancers. Upon completion of this CE activity, participants will be able to: Describe the rationale for using neoadjuvant, adjuv...
Petros Grivas, MD, PhD - Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies
January 10, 2022 23:00 - 1 hour VideoGo online to PeerView.com/RPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With multiple novel therapeutics recently approved for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questio...
Sumanta Kumar Pal, MD, FASCO - Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?
January 06, 2022 23:00 - 55 minutes VideoGo online to PeerView.com/XZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent validation of novel multitargeted TKIs and immune checkpoint inhibitor therapies in metastatic disease, the treatment horizon of renal cell carcinoma (RCC) has vastly expanded and has continued to broaden with the emergence of long-term data supporting the efficacy of dual checkpoint blockade and combination therapies involving immunotherapy/TKI...
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care
December 30, 2021 23:00 - 1 hour VideoGo online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profilin...
David F. McDermott, MD - How I Think, How I Treat: Individualizing RCC Therapy in the Era of Immuno-Oncology
December 28, 2021 23:00 - 1 hour VideoGo online to PeerView.com/TKZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With new developments in the advanced renal cell carcinoma (RCC) treatment landscape, clinicians have more opportunities for personalizing therapeutic approaches for patients with RCC. Validation of novel combinatorial approaches, such as dual checkpoint inhibition and immunotherapy plus targeted agents, have led to FDA approvals, and novel approaches synergist...
David R. Jones, MD - Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC
December 20, 2021 23:00 - 1 hour VideoGo online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Con...
Amit Singal, MD, MS - Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies
December 20, 2021 23:00 - 1 hour VideoGo online to PeerView.com/ZQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Seminar & Multidisciplinary Tumor Board program will pair insightful commentary on emerging systemic and locoregional options in HCC with clinical insights from different disciplines. Each Tumor Board segment will feature a case-centered discussion on the increasingly important multidisciplinary team-based management of patients across the HCC disease cont...
Stephen V. Liu, MD / Bhavesh Shah, RPh, BCOP - Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Managed Care Implications for the "Four Ps": Patient, Provider, Pharmacy, and Plan
December 18, 2021 23:00 - 1 hour VideoGo online to PeerView.com/TMR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and managed care provide a foundational overview of the mechanism of action of cancer immunotherapies and why this class of agents is different from other oncologic therapies. The panel also explores how immunotherapies have revolutionized the management of cancer over the last few years, particularly the ways in which SCLC...